HNF4A and type 2 diabetes mellitus: Metformin, a drug widely used to treat type 2 diabetes, reduces peroxisome proliferator-activated receptor γ coactivator 1α expression and gluconeogenesis in the liver suggesting pharmacological intervention may be successful in decreasing HNF4α-dependent HBV transcription and replication [23], [24].